In the Escalada study (18), insulin naive patients who initiated treatment with Glargine U100 had a slight increase in hypoglycemia, while insulin experienced patients who switched from any basal insulin to Glargine U100 showed less episodes of the outcome. The gene discussed is INS; the disease is Hypoglycemia.